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We have previously characterized the release of the
signal peptide sequence-less fibroblast growth factor
(FGF) prototype, FGF-1, in vitro as a stress-induced
pathway in which FGF-1 is released as a latent ho-
modimer with the p40 extravesicular domain of p65 syn-
aptotagmin (Syn)-1. To determine the biologic relevance
of the FGF-1 release pathway in vivo, we sought to re-
solve and characterize from ovine brain a purified frac-
tion that contained both FGF-1 and p40 Syn-1 and report
that the brain-derived FGF-1:p40 Syn-1 aggregate is as-
sociated with the calcium-binding protein, S100A13.
Since S100A13 binds the anti-inflammatory compound
amlexanox and FGF-1 is involved in inflammation, we
examined the effects of amlexanox on the release of
FGF-1 and p40 Syn-1 in response to stress in vitro. We
report that while amlexanox was able to repress the
heat shock-induced release of FGF-1 and p40 Syn-1 in a
concentration-dependent manner, it had no effect on
the constitutive release of p40 Syn-1 from p40 Syn-1 NIH
3T3 cell transfectants. These data suggest the following:
(i) FGF-1 is associated with Syn-1 and S100A13 in vivo;
(ii) S100A13 may be involved in the regulation of FGF-1
and p40 Syn-1 release in response to temperature stress
in vitro; and (iii) the FGF-1 release pathway may be
accessible to pharmacologic regulation.
The FGF1 prototype, FGF-1, functions as an extracellular
mitogen for a diverse population of target cells, yet it lacks
a classical signal peptide sequence for secretion (1). FGF-1
is released in response to temperature stress in vitro (2)
as a latent FGF-1 Cys-30 homodimer (3, 4) through a
secretion pathway that is independent of the conventional
route mediated by the endoplasmic reticulum (ER)-Golgi ap-
paratus (3) but is sensitive to inhibition by actinomycin D and
cycloheximide (2).
We have partially characterized the latent FGF-1 species
released in vitro in response to temperature stress. The extra-
cellular FGF-1 homodimer is a component of a high molecular
weight aggregate that contains the extravesicular p40 domain
of synaptotagmin (Syn)-1 (5). The full-length Syn-1 translation
product (p65) has been implicated in the regulation of exocy-
totic (6) and endocytotic (7) traffic and, like FGF-1 (4), Syn-1 is
a phosphatidylserine- (8) and heparin-binding protein (9).
Whereas the stress-induced FGF-1 and p40 Syn-1-containing
extracellular aggregate is not biologically active and binds
poorly to immobilized heparin (5), the biological and heparin-
binding properties of FGF-1 can be recovered if the aggregate is
treated with a reducing agent such as reduced glutathione (3)
or with ammonium sulfate (2). It is possible that the latent
character of this FGF-1 aggregate may represent a physiologic
safeguard to ensure that extracellular FGF-1 can only signal if
the extracellular environment is appropriate for the cell to
respond to its stimuli; otherwise, it would be rapidly cleared.
Indeed, cell-surface-associated heparin-sulfate proteoglycans
are thought to not only present FGF-1 to its high affinity
receptor tyrosine kinase (10) but also to protect FGF-1 from
degradation by proteolytic enzymes present in the extracellular
milieu during cell migration and proliferation (11, 12).
Because FGF-1 is released in response to heat shock in vitro
as a reducing agent and denaturant-sensitive aggregate with
p40 Syn-1 (5), and Syn-1 is required for FGF-1 secretion in
response to heat shock (13), we sought to determine whether
FGF-1 and Syn-1 also exist as an aggregate in vivo in order to
provide a physiologic correlate to the in vitro data. Since neural
tissue has served as the traditional source of native FGF-1 (14)
and early evidence suggested that FGF-1 is present in neural
tissue as an acid-sensitive high molecular weight aggregate
(15), we sought to determine whether FGF-1 and p40 Syn-1
could be resolved as a heparin-binding aggregate from neutral
extracts of neural tissue. We report that brain-derived FGF-1
exists as a multiprotein aggregate with p40 Syn-1 and
S100A13, a member of the S100 gene family of calcium-binding
proteins (16, 17) and have been able to utilize a pharmacologic
strategy to illustrate that S100A13 may be a functional com-
ponent of the FGF-1 release pathway.
EXPERIMENTAL PROCEDURES
Materials and Immunoblot Analysis—Amlexanox (also known as
AA673, Amoxanox, and Solfa) and its three derivatives were a very
generous gift of Dr. G. Goto from Takeda Chemical Industries, Osaka,
Japan. All other chemicals were reagent-grade and obtained from
Sigma except where otherwise indicated. Chromatography solvents
were HPLC-grade and obtained from Burdick and Jackson (Muskegon,
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MI). The rabbit polyclonal antibodies against recombinant human
FGF-1 and rat p40 Syn-1 were prepared as described previously (5, 13).
All antibodies were used for immunoblot analysis at a concentration of
4 mg/ml in blocking buffer as described previously (2) except that an
enhanced chemiluminescence (ECL) system (Amersham Pharmacia
Biotech) was used for protein detection.
Preparation of Brain Extracts—Ten (1.5 kg) unstripped ovine brains
(Pel-Freeze® Biologicals, Rogers, AR) were homogenized in 1.3 volumes
of 50 mM Tris-HCl, pH 7.4, for 2 min in a Waring blender. The homo-
genate was centrifuged at 10,000 3 g for 1 h, and the supernatant was
filtered through sterile gauze. The filtrate was subjected to stepwise
salt fractionation with 50 and 95% (NH4)2SO4 saturation, and the
precipitates were collected by centrifugation as described (14). The 95%
(NH4)2SO4 saturation precipitate was resuspended in 100 ml of 50 mM
Tris-HCl, pH 7.4, and dialyzed for 18 h against 50 volumes of the
resuspension buffer using a Spectra/Por (Mr 12–14,000) dialysis mem-
brane (Spectrum Medical Industries Inc., Houston, TX). All purification
procedures were performed at 4 °C.
Chromatographic Analysis of Neutral Brain Extracts—A 2.5 3 22-cm
plastic column containing 25 ml of hydrated heparin-Sepharose CL-6B
was equilibrated with 10 volumes of 50 mM Tris-HCl, pH 7.4, and the
brain extract was adsorbed twice over the immobilized heparin. The
column was washed with at least 10 bed volumes of the resuspension
buffer until the absorbance of the eluate at l 5 280 nm was less than
0.01. Three batch fractions were eluted with 100 ml of 50 mM Tris-HCl,
pH 7.4, containing 0.4 M NaCl, 0.7 M NaCl, and 1.5 M NaCl, and samples
from each NaCl eluate (25 ml) were adsorbed to a C4 column (VydacTM,
Hesperia, CA) conditioned in 0.1% trifluoroacetic acid (Pierce). RP-
HPLC was performed as described (18) using a linear gradient of
acetonitrile (40 to 100%) in 0.1% (v/v) trifluoroacetic acid at a flow rate
of 1 ml/min, and the effluent was monitored at l 5 214 nm. Samples
were collected as absorbance peaks independent of volume in 1.0 M
Tris-HCl, pH 7.4, in an attempt to maintain aggregate integrity and
analyzed by FGF-1 and Syn-1 immunoblot analysis as described (2, 5)
except that the ECL system was used for protein detection. Although
many peaks exhibited the presence of both FGF-1 and Syn-1 by immu-
noblot analysis, only the 1.5 M NaCl heparin-Sepharose elution fraction
contained a unique absorbance peak that contained both FGF-1 and
Syn-1 by immunoblot analysis at a dilution of 1:100. This peak was
re-chromatographed on a microbore 300-Å C4 Aquapore RP300 column
(Perkin-Elmer), and bound proteins were eluted as absorbance peaks at
l 5 214 with a linear gradient (40–100%) of 70% (v/v) acetonitrile in
0.1% (v/v) trifluoroacetic acid and a flow rate of 0.2 ml/min.
Protein Sequencing—Approximately 10 mg of protein from the indi-
cated peaks in Fig. 1, B and C, were subjected to proteolytic digestion
using lysyl endopeptidase C (Boehringer Mannheim) as described (73).
Peptides were isolated by RP-HPLC using an Applied Biosystems model
130 separation system. Isolated peptides were subjected to automated
Edman degradation using either an Applied Biosystems model 473A or
477A protein sequenator. Proteins were identified by comparison of the
amino acid sequences obtained for several of these peptides against an
NCBI (National Center for Biotechnology Information) protein se-
quence data base using the BLAST (Basic Local Alignment Search Tool)
program.
Pharmacology of FGF-1 Release in Response to Heat Shock—NIH
3T3 cell FGF-1 [2] transfectants and FGF-1:b-gal and p65 Syn-1 co-
transfectants (13) were grown to 80% confluence on fibronectin-coated
dishes and subjected to temperature stress (41.5 °C, 90 min) under the
conditions previously described (74). Where indicated, various concen-
trations of either amlexanox or one of its chemical derivatives were
present during the entire heat shock period. A stock solution of amlex-
anox was freshly prepared in equimolar NaOH, and serial dilutions in
phosphate-buffered saline were prepared prior to addition to the cells as
recommended by Takeda chemical Industries Ltd. The compounds were
added in volumes of 160 ml/20 ml of medium. The same volume of NaOH
without drug was also added to the cells and found to have no effect on
either protein release, membrane permeability (lactate dehydrogenase
activity), or cell viability. In addition, cells maintained at 37 °C in the
presence or absence of amlexanox for the same period were used as a
control. Conditioned media were collected and filtered through 0.2-mm
cellulose acetate. Aliquots (300 ml) were taken for analysis of lactate
dehydrogenase enzymatic activity in the conditioned media according to
an adaptation of the original method of Bergmeyer (75) and Sigma
procedure DG1340-UV. The remaining filtrate was treated with fresh
0.1% (w/v) dithiothreitol for 2 h at 37 °C and processed by heparin-
Sepharose chromatography as described (2).
RESULTS
Brain-derived FGF-1 Exists as a Denaturant-sensitive Aggre-
gate with Syn-1—Extracts of ovine brain were prepared at a
neutral pH and subjected to (NH4)2SO4 precipitation (50 and
95% saturation) as described under “Experimental Proce-
dures.” The 95% (NH4)2SO4 saturation precipitate was resus-
pended as described previously (18) and separated into three
batch-eluted fractions (0.4, 0.7, and 1.5 M NaCl) by heparin-
Sepharose chromatography. Whereas immunoblot analysis of
each eluate revealed the presence of both FGF-1 and p40 Syn-1
in all three fractions, only the 1.5 M NaCl post-heparin-Sepha-
rose eluate was able to produce a reversed phase (RP)-HPLC
peak (Fig. 1A) that contained both FGF-1 and p40 Syn-1 by
immunoblot analysis (data not shown). The presence of p40
Syn-1 in the 1.5 M NaCl post-heparin-Sepharose elution frac-
tion was unexpected since recombinant p40 Syn-1 has been
observed to elute at a lower (;0.6 M NaCl) ionic strength [5]. To
ensure that the post-RP-HPLC heparin-binding fraction con-
taining both FGF-1 and p40 Syn-1 did not contain additional
non-associated proteins, this fraction was again subjected to
analysis by RP-HPLC. As shown in Fig. 1B, RP-HPLC analysis
revealed a single symmetrical peak with a retention time iden-
tical to that previously observed (Fig. 1A). Immunoblot analy-
sis using FGF-1 and Syn-1 antibodies confirmed the presence of
both FGF-1 and p40 Syn-1 in this sample (Fig. 2, A and B).
Since this fraction (Fig. 1B) contained both FGF-1 and p40
Syn-1 and the electrophoretic mobility of the FGF-1:Syn-1 ag-
gregate released in response to temperature stress is denatur-
ant-sensitive (5), we anticipated that treatment of this fraction
with a chaotropic agent should resolve the FGF-1 and Syn-1
components as individual peaks with RP-HPLC retention
times identical to their retention times defined by both the
native (Fig. 1A) and recombinant (Fig. 1D) proteins. Therefore,
the brain-derived, post-RP-HPLC fraction (Fig. 1B) containing
both FGF-1 and p40 Syn-1 was heated (5 min, 95 °C) in the
presence of 8.0 M guanidine HCl and analyzed by RP-HPLC. As
shown in Fig. 1C, the fraction containing both FGF-1 and p40
Syn-1 was present, but its absorbance was reduced signifi-
cantly. In addition, numerous fractions with distinct retention
times were readily visible including a major absorption peak
and fractions previously defined as FGF-1 and p40 Syn-1 (Fig.
1, A and D). These data suggest that thermal and guanidine
HCl denaturation of the brain-derived post-RP-HPLC fraction
(Fig. 1B) containing both FGF-1 and p40 Syn-1 generates ad-
ditional fractions with different retention times including
peaks with retention times identical to FGF-1 and p40 Syn-1.
Thus it is likely that this brain-derived, heparin-binding frac-
tion represents an aggregate that contains FGF-1 and p40
Syn-1 as well as other temperature- and chaotropic-sensitive
components.
The S100 Gene Family Member, S100A13, Is a Component of
the Brain-derived FGF-1 and p40 Syn-1 Aggregate—Since the
major absorption fraction containing both FGF-1 and p40
Syn-1 (Fig. 1B) demonstrated an unknown retention time, we
sought to determine its structure. However, automated Edman
degradation of this peak failed to yield any information. There-
fore, this fraction (Fig. 1B) was subjected to LysC digestion,
and the peptides were resolved by RP-HPLC. Automated Ed-
man degradation of these peptides demonstrated that this frac-
tion contained a member of the S100 gene family (17), the ovine
homolog of human S100A13 (16). Interestingly, the structure of
the S100A13 protein predicted from the bovine (GenBankTM
accession number AB001567), murine, and human cDNA se-
quences (16) suggests that S100A13 contains 98 amino acid
residues, 9 of which have cyclic side chains that absorb in the
far-UV area used for detection (19, 20). Thus, the high UV
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absorbance feature of the FGF-1 and p40 Syn-1 aggregate (Fig.
1B) may be due in part to the extinction coefficient of S100A13
(Fig. 1, C and D). Since it was possible to resolve a single
fraction from RP-HPLC whose retention time was altered by
treatment with temperature and the chaotropic agent, guani-
dine HCl, we suggest that S100A13 is a component of a multi-
protein FGF-1- and p40 Syn-1-containing aggregate and that
S100A13 is also present in this aggregate as a protein with a
blocked amino terminus.
It is important to note that the major absorption peak in Fig.
1C, resulting from the denaturation of the fraction (Fig. 1B)
containing FGF-1, p40 Syn-1, and S100A13, exhibited a dis-
tinct retention time, yet immunoblot analysis of this major
absorption peak demonstrated the presence of low levels of
FGF-1 and p40 Syn-1 (data not shown). Since members of the
S100 gene family are known to self-associate (21) and to asso-
ciate with membrane phospholipids (22), it is possible that the
major absorption peak in Fig. 1B may contain S100A13 aggre-
gates as well as other peptidic and non-protein components
such as acidic phospholipids. Thus, denaturation of the mul-
timeric aggregate in Fig. 1B containing p40 Syn-1, S100A13,
and FGF-1, with temperature and treatment with guanidine
HCl resulted in only a partial disruption of the aggregate. In
addition, we cannot eliminate the possibility that the FGF-1,
p40 Syn-1, and S100A13-containing peak resolved in Fig. 1, A
and B, is the result of nonspecific protein aggregation under
RP-HPLC conditions. However, it is noteworthy that recombi-
nant S100A13 elutes from immobilized heparin between 0.2
and 0.4 M NaCl (data not shown), and recombinant p40 Syn-1
elutes from heparin-Sepharose at 0.7 M NaCl (5). Since the
brain-derived, post-heparin-Sepharose fraction containing p40
Syn-1, FGF-1, and S100A13 was isolated as a high affinity (1.5
M NaCl elution peak) heparin-binding fraction prior to resolu-
tion by RP-HPLC, it is likely that S100A13 and p40 Syn-1
gained high heparin binding affinity through their ability to
associate with FGF-1 prior to analysis by RP-HPLC.
Interestingly, automated Edman degradation of the FGF-1
fraction (Fig. 1C) derived from treatment of the FGF-1,
S100A13, and p40 Syn-1 aggregate (Fig. 1B) with temperature
and guanidine HCl also failed to yield information. However,
automated Edman degradation of LysC fragments derived
from the FGF-1 peak (Fig. 1C) demonstrated that it was pres-
ent as a protein with a blocked amino terminus that has pre-
viously been characterized as FGF-1b (residues 1–154) (23).
Unfortunately, however, it was not possible to collect sufficient
material from the p40 Syn-1 peak described in Fig. 1C for
structural analysis, but it was possible to confirm the identity
of this peak by Syn-1 immunoblot analysis (data not shown).
Likewise, automated Edman degradation of the remaining
peaks described in Fig. 1C did not yield any information, and
sufficient material was not available for analysis by LysC di-
gestion. These data imply that the ovine brain-derived, hepa-
rin-binding and denaturant-sensitive aggregate resolved by
RP-HPLC (Fig. 1B) contains at least FGF-1b, p40 Syn-1, and
S100A13. Furthermore, these data also provide an in vivo
correlate to the presence of FGF-1 and p40 Syn-1 as a dena-
time and resolve it as a single peak. C, the fraction obtained after two
consecutive runs containing FGF-1, Syn-1, and S100A13 was treated
with of 8 M guanidine HCl in 0.25 M Tris-HCl, pH 8.5, vortexed for 1
min, heated for 5 min at 95 °C, vortexed for 1 min, and allowed to cool
to room temperature before separation by RP-HPLC on a microbore
column. Fractions were collected as absorbance peaks, divided in two,
and subjected to FGF-1 and Syn-1 immunoblot analysis and protein
sequencing. D, samples of purified human recombinant FGF-1, rat
recombinant Syn-1, and murine recombinant S100A13 were initially
resolved by RP-HPLC to identify the retention time for each protein
(data not shown) and then resolved as a mixture by RP-HPLC.
FIG. 1. Purification of a heteromeric aggregate containing
FGF-1, Syn-1, and S100A13 from ovine brain. Ovine brain extract
was prepared and separated into three fractions by heparin-Sepharose
chromatography as described under “Experimental Procedures.” Data
are reported as a function of relative absorbance and retention time.
The solid line on the chromatogram indicates the development of the
acetonitrile gradient. A, RP-HPLC analysis of 25 ml of the post-heparin-
Sepharose 1.5 M NaCl eluate. Fractions were collected as absorbance
peaks into equal volumes of 1 M Tris-HCl, pH 7.4, to conserve aggregate
integrity. Aliquots were taken along the chromatogram and probed for
the presence of FGF-1 and Syn-1 by immunoblot analysis (data not
shown). Although the majority of these fractions contained either
FGF-1, Syn-1 or both, the fractions identified as FGF-1 and Syn-1 were
determined by their presence as FGF-1 and Syn-1 immunoblot-positive
samples at a dilution of 1:100. The presence of S100A13 was confirmed
by microsequencing. B, the peak containing FGF-1, Syn-1, and S100A13
from A was rechromatographed by RP-HPLC to confirm its retention
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turant-sensitive aggregate that is released into the extracellu-
lar compartment in response to temperature stress in vitro (5).
The S100A13-binding, Anti-allergic, and Anti-inflammatory
Drug, Amlexanox, Represses the Stress-induced Release of
FGF-1 and p40 Syn-1 in Vitro—Because (i) S100A13 was pu-
rified as an aggregate with FGF-1 and p40 Syn-1 from ovine
brain, (ii) elevated FGF-1 levels are associated with inflamma-
tory environments in vivo (24), (iii) Syn-1 is released as a p40
fragment in response to temperature stress (5) and is required
for heat shock-induced FGF-1 secretion (13), (iv) the anti-in-
flammatory and anti-allergic compound, amlexanox, binds
S100A13 (Ref. 25; GenBankTM accession number AB001567),
(v) amlexanox is able to interfere with the release of intracel-
lular granules from basophils and mast cells (26), and (vi) NIH
3T3 cells express the S100A13 transcript (data not shown), we
sought to determine whether amlexanox would be able to mod-
ify the stress-induced release of FGF-1 and p40 Syn-1 from
NIH3T3 cells in vitro. NIH 3T3 cell FGF-1:b-galactosidase
(Gal) and p65 Syn-1 co-transfectants were subjected to temper-
ature stress (90 min, 41.5 °C) as described previously (13) in
the absence and presence of amlexanox. The conditioned me-
dium was treated with dithiothreitol, adsorbed to heparin-
Sepharose, and the presence of FGF-1:b-gal and Syn-1 assessed
by immunoblot analysis as described previously (2). As shown
in Fig. 3, A and B, amlexanox was able to repress the release of
both FGF-1:b-gal and p40 Syn-1 in response to temperature
stress. The inhibition of FGF-1:b-gal and p40 Syn-1 release was
dependent upon the concentration of amlexanox and was
within the concentration range that exhibits pharmacologic
effects as an anti-allergic and anti-inflammatory agent (27–29).
Similar amlexanox concentrations were also able to inhibit the
release of FGF-1 from FGF-1 NIH 3T3 cell transfectants in
vitro (Fig. 5). Because of the possibility that amlexanox may
also possess broad inhibitory activity upon conventional cellu-
lar secretion, we evaluated the ability of amlexanox to repress
the release of a synthetic form of FGF-1 engineered to enter
into the conventional ER-Golgi-mediated secretion pathway
(30). Exposure of NIH 3T3 cells stably transfected with the
FGF-4 signal peptide sequence: FGF-1 chimera (30) to amlex-
anox did not result in inhibition of the constitutive secretion of
the FGF-1 chimera (data not shown). Furthermore, the forced
secretion of FGF-1 is known to induce a prominent transformed
NIH 3T3 cell phenotype in vitro (30), and amlexanox was
unable to modify this phenotype. Additionally, the p40 extrave-
sicular fragment of Syn-1 is constitutively released in p40
Syn-1 NIH 3T3 cell transfectants, and this release is potenti-
ated by heat shock treatment (13). Whereas this constitutive
release of p40 Syn-1 occurs by an unknown pathway, the tem-
perature-enhanced release of p40 from these cells appears to
utilize the regulated FGF-1 release mechanism (13). Thus, we
examined the ability of amlexanox to influence the release of
p40 Syn-1 from the NIH 3T3 cell p40 Syn-1 transfectants, and
we observed that amlexanox was not able to block the consti-
tutive release of p40 from cells maintained at 37 °C (Fig. 4,
lanes 1, 3 and 4). However, amlexanox was able to repress the
temperature-sensitive component of p40 Syn-1 release (Fig. 4,
lane 5 versus lane 2) in vitro. Finally, all experiments were
monitored for cell lysis and changes in the permeability of the
plasma membrane by measuring the levels of the cytosolic
enzyme lactate dehydrogenase in the conditioned media of all
samples, and no significant differences in extracellular lactate
dehydrogenase levels were observed among the various treat-
ments and conditions. We therefore suggest that amlexanox,
the S100A13-binding compound, is able to significantly repress
the temperature stress-induced release of both FGF-1 and p40
Syn-1.
Chemical Modification of Amlexanox Reduces its Ability to
Repress the Release of p40 Syn-1 and FGF-1 in Response to
Temperature Stress in Vitro—To provide a structural basis for
the ability of amlexanox to repress the release of FGF-1 and
p40 Syn-1 from its full-length (p65 Syn-1) precursor in vitro, we
obtained several chemical derivatives of amlexanox (Fig. 5)
with variable anti-allergic and anti-inflammatory activities.
Each amlexanox derivative was evaluated for its ability to
FIG. 2. Immunoblot analysis of the S100-containing fraction. The fraction corresponding to the major chromatographic peak shown in Fig.
1B was divided in two, and each aliquot was independently resolved by SDS-PAGE (12.5% acrylamide) under reducing conditions as described
under “Experimental Procedures.” Lane 1 contains 50 ng of recombinant rat Syn-1 protein; lane 2 contains 50 ng of recombinant human FGF-1a
(residues 21–154); lane 3 contains the chromatographic peak obtained from Fig. 1B. A represents the Syn-1 immunoblot and B the FGF-1
immunoblot. Note that the FGF-1 species present in the S100A13 peak (lane 3) migrates with a higher relative molecular weight than the
recombinant species (FGF-1a, residues 21–154), and this is consistent with its identification as the full-length form of FGF-1 (FGF-1b, residues
1–154) [18].
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decrease the release of both FGF-1 and p40 Syn-1 from NIH
3T3 cell FGF-1 transfectants in response to temperature stress
in vitro. As shown in Fig. 5, immunoblot analysis of media
conditioned by heat shock in the presence or absence of either
amlexanox (AA673) or one of its derivatives revealed that while
derivatives AA617 and AA648 were able to repress FGF-1
release, derivative AA777 was not able to do so. Syn-1 immu-
noblot analysis of these samples also demonstrated that aml-
exanox derivatives AA617 and AA648 but not derivative AA777
were able to inhibit the release of p40 Syn-1 from endogenous
p65 Syn-1 in response to temperature stress (data not shown).
These data suggest that either substitution of the isopropyl
side chain with an acetyl group or deletion of the amino group
at the opposite end of the molecule does not reduce the ability
of amlexanox to repress FGF-1 and p40 Syn-1 release in re-
sponse to temperature stress in vitro. However, substitution of
the isopropyl side chain with a methyl group generates an
amlexanox derivative that is unable to repress the release of
either FGF-1 (Fig. 5) or p40 Syn-1 (data not shown) in response
to heat shock. These data suggest that the major functional
group within the structure of amlexanox that is able to modify
FGF-1 and p40 Syn-1 release is the hydrophobic side chain,
including the maintenance of at least a two-carbon unit.
DISCUSSION
We have utilized primarily in vitro methods to characterize
the mechanism for the extracellular release of FGF-1 as a
non-conventional release pathway since brefelden A, a drug
which disrupts the classical ER-Golgi secretion pathway, does
not inhibit the release of FGF-1 in response to temperature
stress (2, 3). Within the extracellular compartment in vitro,
FGF-1 exists as a latent Cys-30 homodimer (3) associated with
the p40 extravesicular domain of Syn-1 (5). This aggregate is
detergent- and reducing agent-sensitive, and electrophoretic
mobility shift analysis anticipated the presence of additional
components (5). In order to determine whether the information
obtained from the characterization of the FGF-1 release path-
way in vitro could be applied to an in vivo situation, we pursued
the isolation of a multiprotein aggregate from ovine brain that
contained FGF-1 and p40 Syn-1, and we report that the brain-
derived FGF-1:Syn-1 aggregate also contains the calcium-bind-
ing protein, S100A13 (16), a member of the S100 gene family of
EF-hand-containing Ca21-binding modulator proteins (17).
The S100 gene family members (31) encode low molecular
weight acidic polypeptides containing two Ca21-binding EF-
hand motifs flanked by two hydrophobic domains (17, 32).
S100A13 also exhibits these structural features, and in con-
trast with other S100 gene family members, it contains a car-
boxyl-terminal domain that is rich in basic amino acid residues
(16). Whereas all tissues express at least one member of the
S100 gene family, the cellular distribution is specific for mem-
bers of the S100 gene family (17). In this regard it is interesting
that like FGF-1 (1) and Syn-1 (33), S100 proteins are highly
enriched in neural tissue (34, 35). However, S100A13 expres-
sion is not limited to neural tissue, and with the possible
exception of leukocytes, S100A13 expression is ubiquitous in
other organs, tissues, and cell types (16) including its presence
in NIH 3T3 cells. Interestingly, some members of the S100 gene
family have been found to be associated with the nucleus (36),
although most are cytosolic and can be associated with the
endoplasmic reticulum and actin stress fibers (37). However,
like FGF-1 (2), several S100 gene family members are released
from cells in vitro (17, 38) despite the absence of a conventional
signal peptide sequence for classical ER-Golgi-mediated secre-
tion. Furthermore, even though no specific cell-surface receptor
has been identified for these extracellular S100 gene family
members (34, 39), some do possess extracellular functions in-
cluding the regulation of neuronal differentiation (40–42),
the stimulation of melanoma and glial cell proliferation and
migration (35, 43), and chemotactic activities (44, 45). Indeed,
it is interesting that FGF-1 is also able to accomplish these
functions as well (1).
Since S100A8 and S100A9 are released from monocytes
through a novel ER-Golgi-independent pathway that requires
an intact tubulin network (38), it is not perhaps surprising that
S100A13 may be a component of the FGF-1 and p40 Syn-1
ER-Golgi-independent release pathway. Indeed, the release of
S100A8 by monocytes and activated neutrophils coincides with
the release of the pro-inflammatory cytokine, interleukin
(IL)-1a by these cells (46). This is interesting since the IL-1 and
FGF gene family prototypes most likely evolved without clas-
sical signal peptide sequences from a common primordial gene
(23). The IL-1 and the FGF gene family prototypes also exhibit
sequence homologies (47, 48) including very similar crystallo-
graphic structures (49, 50). Like S100A8 and the IL-1 proto-
types, FGF-1 is also expressed during inflammatory situations
in vivo (24) and is thought to be released during these situa-
tions. Thus, it is also not surprising that the anti-allergic and
anti-inflammatory S100A13-binding compound, amlexanox
((25) GenBankTM accession number AB001567), is able to re-
FIG. 3. The effect of amlexanox on the release of the FGF-1:b-
Gal chimera and p40 Syn-1 into media conditioned by NIH 3T3
cell FGF-1:b-Gal and p65 Syn-1 co-transfectants exposed to tem-
perature stress. Media were conditioned by two 150-mm dishes of
NIH 3T3 cells stably transfected with human FGF-1:b-Gal and rat p65
Syn-1 by exposure to 41.5 °C for 90 min. The media were collected and
resolved by 10% acrylamide SDS-PAGE under reducing conditions fol-
lowed by immunoblot analysis for FGF-1 and Syn-1 as described under
“Experimental Procedures.” A, FGF-1 immunoblot analysis. 1st lane,
media derived from FGF-1:b-Gal and p65 Syn-1 NIH3T3 cell co-trans-
fectants maintained at 37 °C for 90 min. 2nd lane, media derived from
FGF-1:b-Gal and p65 Syn-1 NIH3T3 cell co-transfectants following
heat shock in the absence of any drug; 3rd to 5th lanes, media derived
from FGF-1:b-Gal and p65 Syn-1 NIH3T3 cell co-transfectants follow-
ing heat shock in the presence of 0.8 3 1026, 5 3 1025, and 1024 M
AA673 (amlexanox), respectively; 6th lane, 50 ng of recombinant human
FGF-1a:b-Gal and 50 ng of recombinant rat p40 Syn-1. B, Syn-1 immu-
noblot analysis; the filter was stripped according to the manufacturer’s
instructions (Amersham Pharmacia Biotech) and re-probed for Syn-1.
Lane descriptors are identical to those described in A.
The FGF-1 Release Pathway III22228
press the release of FGF-1 and p40-Syn-1 in response to tem-
perature stress in vitro.
Although we have not determined whether S100A13 is re-
leased in a brefelden A-insensitive manner with FGF-1 and p40
Syn-1 in response to cellular stress in vitro, our data do suggest
that S100A13 may be at least a component of the intracellular
multiprotein aggregate involved in the regulation FGF-1 re-
lease. Interestingly, S100 proteins (22) Syn-1 (8) and FGF-1 (4)
are all well characterized as acidic phospholipid-binding pro-
teins and since the p40 Syn-1 and FGF-1 components of the
aggregate released from cells in response to heat shock are
sensitive to denaturing agents, it is possible that the ability of
these proteins to interact with phosphatidylserine may be a
common feature of other unknown protein components of this
release pathway. Indeed, gel shift analysis of the denaturant-
sensitive component of the low heparin-binding affinity p40
Syn-1 and FGF-1 aggregate (5) anticipated the presence of a
protein (;10 kDa) with an apparent molecular weight similar
to that predicted from the S100A13 cDNA (16).
Since the FGF prototypes are well known for their angio-
genic potential (47, 48) and tumor metastasis and growth is
dependent upon tumor angiogenesis in vivo (51, 52), it is also
not surprising that the expression of many of the S100 gene
family members correlates with metastatic tumor potential
(53–56), and in one instance is diagnostic for human melanoma
metastatic potential (57, 58). Indeed, it is possible that S100
gene family members support neoplastic and pro-inflammatory
situations in vivo by their ability to participate in the release
pathway for extracellular signal peptide-less angiogenic and
inflammatory signals such as FGF-1 and IL-1a. Interestingly,
several S100 gene family members are also known to interact
with members of the annexin gene family (59–61), and like
Syn-1 and S100 gene family members, the annexins are Ca21-
dependent acidic phospholipid-binding proteins (62). Annexin
II is a particularly interesting member of this family since it
has been implicated in the regulation of exocytosis (63, 64), and
this activity appears to be mediated by its ability to be associ-
ated with S100A10 (p11) to form an annexin II2-p112 aggregate
(65, 66). Whereas annexin II is known to interact with plas-
minogen and plasminogen activators on the cell surface (67),
annexin II, like S100A13 and FGF-1, does not contain a clas-
sical signal sequence for ER-Golgi-mediated secretion (63, 68).
FIG. 4. Amlexanox does not repress the release of constitutively secreted p40 Syn-1 from NIH 3T3 cell p40 Syn-1 and FGF-1:b-Gal
co-transfectants. Media were conditioned by two 150-nm dishes of NIH 3T3 cells stably co-transfected with FGF-1:b-Gal and rat p40 Syn-1 after
exposure to temperature stress (41.5 °C, 90 min) with or without treatment. The media were collected and resolved by 10% acrylamide SDS-PAGE
under reducing conditions followed by immunoblot analysis for Syn-1 as described under “Experimental Procedures.” 1st lane, media derived from
NIH 3T3 cell FGF-1:b-Gal and p40 Syn-1 co-transfectants maintained at 37 °C for 90 min. 2nd lane, media derived from NIH 3T3 cell FGF-1:b-Gal
and p40 Syn-1 co-transfectants following heat shock. 3rd and 4th lanes, media derived from NIH 3T3 cell FGF-1:b-Gal and p40 Syn-1
co-transfectants maintained at 37 °C in the presence of 5 3 1025 and 3 3 1024 M AA673 (amlexanox), respectively. 5th lane, media derived from
NIH 3T3 cell FGF-1:b-Gal and p40 Syn-1 co-transfectants following heat shock in the presence of 3 3 1024 M, AA673. 6th lane, 50 ng of recombinant
rat p40 Syn-1.
FIG. 5. The effect of amlexanox and its derivatives on the release of FGF-1 into media conditioned by NIH 3T3 cell FGF-1
transfectants exposed to temperature stress. Media were conditioned by three 150-mm dishes of NIH 3T3 cells stably transfected with
FGF-1a (residues 21–154) after exposure to 41.5 °C for 90 min with or without amlexanox and its derivatives. The media were collected and
resolved by 12.5% acrylamide SDS-PAGE under reducing conditions followed by immunoblot analysis for FGF-1 as described under “Experimental
Procedures.” 1st lane, media derived from NIH 3T3 cell FGF-1 transfectants following heat shock in the absence of any drug; 2nd to 4th lanes,
media derived from NIH 3T3 cell FGF-1 transfectant following heat shock in the presence of 1 3 1026, 1 3 1025, and 1 3 1024 M AA673
(amlexanox), respectively; 5th to 7th lanes, media derived from NIH 3T3 cell FGF-1 transfectants following heat shock in the presence of 1 3 1026,
1 3 1025, and 1 3 1024 M AA617, respectively; 8th to 10th lanes, media derived from NIH 3T3 cell FGF-1 transfectants following heat shock in
the presence of 1 3 1026, 1 3 1025, and 1 3 1024 M AA648, respectively; 11th to 13th lanes, media derived from NIH 3T3 cell FGF-1 transfectants
following heat shock in the presence of 1 3 1026, 1 3 1025, and 1 3 1024 M AA777, respectively; 14th lane, media derived from NIH 3T3 cell FGF-1
transfectants maintained at 37 °C for 90 min; 15th lane, 50 ng of recombinant human FGF-1a. The structure of amlexanox (AA673) and its
derivatives are also shown.
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Although it is not known whether S100A13 is able to interact
with annexin II on the inner surface of the plasma membrane,
annexins I through V were identified together with S100A13 as
amlexanox-binding proteins (25).
The ability of amlexanox to repress the release of FGF-1 and
the extravesicular p40 domain of p65 Syn-1 from NIH 3T3 cells
in response to heat shock is noteworthy since S100A13 is an
amlexanox-binding protein (25). Thus it is possible that aml-
exanox may interfere with the putative interaction between
intracellular S100A13 and the FGF-1 and Syn-1 aggregate.
Since amlexanox does not repress the appearance of the con-
stitutively released p40 Syn-1 fragment in vitro, it is possible
that amlexanox may be able to target the interaction between
S100A13 and the putative FGF-1 and p65 Syn-1 aggregate.
However, it is also possible that amlexanox may be interactive
with other intracellular acidic phospholipid-binding proteins
including members of the annexin gene family. Indeed, it is
intriguing that the S100A13 (22), FGF-1 (4), and Syn-1 (8)
components of this novel release pathway bind membrane
phospholipids, since the ability of amlexanox to interfere with
either the metabolism or the membrane release of lipid medi-
ators of the inflammatory response, such as arachidonic acid
derivatives, has served as the basis to explain the mechanism
of action of amlexanox pharmacology (26–29).
Access to structural analogs of amlexanox has enabled us to
define the importance of the isopropyl side chain as a func-
tional element of its ability to repress the heat shock-induced
release of FGF-1 and p40 Syn-1 in vitro. Since the modification
of the amino group as well as conversion of the isopropyl side
chain to an ethyl group did not influence the effectiveness of
amlexanox to repress FGF-1 release in response to tempera-
ture stress, we suggest that these derivatives may serve as
appropriate negative controls for these in vitro studies. Indeed,
the general effect of these drugs on membrane permeability
was measured by the release of lactate dehydrogenase, and
amlexanox was not able to augment the presence of lactate
dehydrogenase in the extracellular compartment under any
condition. Interestingly, cromolyn, the parent drug used as the
model for the development of amlexanox (69, 70), was also able
to inhibit in a dose-dependent manner the release of FGF-1 and
p40 Syn-1 from NIH 3T3 cell FGF-1 transfectants in response
to temperature stress, but the data are not shown because
contrary to amlexanox, cromolyn treatment resulted in signif-
icant dose-dependent increases in membrane permeability as
measured by the presence of cytosolic lactate dehydrogenase in
the extracellular compartment.
These data also reinforce the biological significance of the
FGF-1 release pathway previously elucidated by the use of in
vitro methods (2–5, 13) since insight into the role of S100A13 as
a potential participant in the FGF-1 release pathway was de-
rived from in vivo data using extracts of ovine brain. Since (i)
the brain-derived aggregate appears to be partially resistant to
both temperature denaturation and treatment with guanidine
HCl, (ii) the known components of the brain-derived multipro-
tein aggregate bind acidic phospholipids, and (iii) the func-
tional group within the structure of amlexanox responsible for
the inhibition of FGF-1 and p40 Syn-1 release in vitro is the
non-polar isopropyl side chain, we anticipate that phospholipid
metabolism may not only play an important role in the mech-
anism of FGF-1 homodimer release but also in the regulation of
the unknown intracellular responsibilities assumed by the
FGF-1 monomer. With regard to the latter, we suggest that
since S100 gene family members are well characterized as
calcium-binding proteins that have calmodulin-like activities
(17, 32, 35, 45), this function may involve structural aspects of
thefilamentouscytoskeletonandtargetsoftheCa21/calmodulin-
dependent protein kinases.
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